Nuvation Bio Stock Earnings Reports

Nuvation Bio reported Q1 2026 results and business updates highlighted by continued commercial traction for Iptrozy (talotrectinib) in ROS1-positive NSCLC and advancing pipeline programs (safusitinib and ADC platform). Key commercial points: ~200 new patient starts for the third consecutive quarter (total >600 since launch), with a meaningful shift toward first-line (TKI‑naive) patients — for the first time >50% of new starts were treatment‑naive — driving improved revenue dynamics (“revenue stacking”). Iptrozy real‑world durability and tolerability remain strong, with pooled TRUST data showing ~50 months median duration of response / PFS in TKI‑naive patients and encouraging intracranial activity; Iptrozy was added to NCCN CNS guidelines. Financial highlights: total revenue $83.2M in Q1, including $18.5M net U.S. product revenue (up 18% sequentially) and $64.7M collaboration/license revenue (including ~$60M upfront from Eisai). Gross‑to‑net expanded as expected; management expects stabilization in the high‑20s to ~30% range. Cash, cash equivalents, and marketable securities were $533.7M, plus $50M available on term loan and an expected ~$30M Eisai milestone upon EU approval in 2027 — management states no need for additional external financing to execute the current plan. Pipeline: safusitinib (IDH1‑mutant glioma) advancing — Phase 3 SIGMA ongoing and rights in Japan secured — and additional clinical and preclinical data to be presented at upcoming meetings. Management emphasized continued focus on increasing testing in the community to grow the diagnosed/addressable ROS1 patient population and on transitioning future investor updates from new patient starts to revenue as the launch matures.